In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Avant sells Paul Royalty an interest in Rotarix

Executive Summary

An affiliate of Paul Royalty Fund II will pay up to $61mm for a stake in Avant Immunotherapeutics' net royalties on worldwide sales of Rotarix, an oral rotavirus vaccine that Avant has licensed to GlaxoSmithKline; in most territories the royalty rate will range from 7-10%. Rotavirus is the main cause of acute pediatric diarrhea and dehydration and can be fatal.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies